NSABP B 23--SHORT INTENSIVE AC W/WO TAMOXIFEN W/ CONVENTIONAL CMF

目前正在进行的研究是为了确定阿霉素和环磷酰胺联合或不联合他莫昔芬治疗4个周期是否比环磷酰胺、甲氨蝶呤和5-氟尿嘧啶联合或不联合他莫昔芬治疗6个周期更有效。淋巴结阴性的乳腺癌患者，病理肿瘤大小为bbb1.0 cm，接受过乳房肿瘤切除术或全乳房切除术和腋窝清扫手术，且其肿瘤雌激素受体经右旋糖酐包被炭法或蔗糖密度梯度法检测发现胞浆蛋白< 10 fmol/mg，或经酶免疫分析法检测发现胞浆蛋白< 15 fmol/mg，将符合条件。如果使用免疫细胞化学测定（ER-ICA）并报告为阴性，也可以接受。必须进行某种形式的黄体酮受体分析并提交结果。黄体酮分析可包括定量或定性（PR-ICA）方法。患者将根据年龄、临床肿瘤大小和手术类型进行分层。

The current study is being conducted to determine whether administering Adriamycin and Cyclophosphamide with or without tamoxifen for four cycles is more effective than administering cyclophosphamide, methotrexate, and 5-fluorouracil for six cycles with or without tamoxifen. Women with node-negative breast cancer and pathological tumor size > 1.0 cm who have undergone lumpectomy or total mastectomy and axillary dissection and whose tumor estrogen receptors have been assayed and found to be < 10 fmol/mg cytosol protein by either the dextran-coated charcoal or sucrose-density gradient methods, or < 15 fmol/mg by the enzyme immunoassay method will be eligible. If the immunocytochemical assay (ER-ICA) is used and is reported as negative, it will also be acceptable. Some form of progesterone- receptor analysis must be perfomred and the results submitted. Progesterone analysis may include quantitative or qualitative (PR-ICA) methods. Patients will be stratified by age, clinical tumor size, and type of operation.